5-(4-Bromophenyl)-4-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)-6-chloropyrimidine

Catalog No. :
ACRYIY942
CAS No. :
1642873-05-9
Molecular Formula :
C16H11Br2ClN4O2
Molecular Weight :
486.55

IUPAC Name:5-(4-bromophenyl)-4-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)-6-chloropyrimidine

5-(4-Bromophenyl)-4-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)-6-chloropyrimidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-(4-Bromophenyl)-4-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)-6-chloropyrimidine
IUPAC Name5-(4-bromophenyl)-4-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)-6-chloropyrimidine
MDL No.MFCD32068474
Molecular FormulaC16H11Br2ClN4O2
Molecular Weight486.55
SMILESClC1=C(C2=CC=C(Br)C=C2)C(OCCOC3=NC=C(Br)C=N3)=NC=N1
InChI KeyHNYIQHYZJIBCRO-UHFFFAOYSA-N
SynonymPyrimidine, 5-(4-bromophenyl)-4-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-6-chloro-;5-(4-Bromophenyl)-4-(2-[(5-bromopyrimidin-2-yl)oxy]ethoxy)-6-chloropyrimidine;5-(4-bromophenyl)-4-({2-[(5-bromopyrimidin-2-yl)oxy]ethyl}oxy)-6-chloropyrimidin;5-(4-Bromophenyl)-4-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-6-chloropyrimidine;Aprocitentan Impurity 36
CAS No.1642873-05-9

Synthetic Route by SureRoute

1. ACRYIY942 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACYHLG741 route compound structure diagram
    ACYHLG741146533-41-7 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRYIY942 route product structure diagram
    ACRYIY9421642873-05-9
Inquiry

2. ACRYIY942 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACJMSY940 route compound structure diagram
    ACJMSY94032779-36-5 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRYIY942 route product structure diagram
    ACRYIY9421642873-05-9
Inquiry

Comments (0)